insulin drugs glp 1 receptor agaonist market GLP-1 Agonist Size, Share Glp-1 Analogues Market Size, Share
Description
The glucagon-like peptides
Exenatide administered once weekly as opposed to twice daily was found to lower HbA1c more significantly in the DURATION- 1 and DURATION- 5 trials ( 1.9% vs
Breast Cancer Prevention The findings demonstrate that GLP-1 users had nearly 30% lower odds of being diagnosed with breast cancer
Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimers disease
J Biol Chem 2001;276:3778793.ArticlePubMed 41
